News

Pursuant to the special protocol assessment, this Phase III trial will be a randomized, double-blind, placebo-controlled trial of IMC-1121B plus docetaxel in women with unresectable locally-recurrent or metastatic

The study is being supported by a Small Business Innovative Research grant awarded from the National Institutes of Health. The total amount of the grant, $3 million, will

David Snow Jr., Medco chairman and CEO, said: “We look forward to the next generation of collaboration with UnitedHealth Group, delivering innovative, world-class pharmacy services. This agreement advances

The company has begun dosing healthy volunteers with ATI-9242 in a Phase I safety study being conducted under an investigational new drug application. ARYx expects to complete the

BLISS-52 was initiated in May 2007, and has enrolled and randomized a total of 867 patients at 90 clinical sites in 13 countries, primarily in Asia, South America

The new development program will examine direct (intravesical) administration of LOR-2040 into the bladder as a treatment for superficial or non-invasive bladder cancer. Formal toxicology evaluation, which is

Propel is a pivotal Phase II, international, multi-center, open-label, single-arm study that enrolled patients with relapsed or refractory PTCL who progressed after at least one prior treatment. Patients

The two companies will continue their joint efforts to identify novel small molecule therapeutics with the potential to treat several diseases, including type 2 diabetes and other metabolic

Replidyne took this action to conserve its cash assets and support initiatives that include pursuing strategic transactions and maintaining its research programs. The acute exacerbation of chronic bronchitis